A clinical phase I study of an EB66 cell-derived H5N1 pandemic vaccine adjuvanted with AS03.

Tanabe, Tetsuro; Ichikawa, Munetaka; Oda, Yoshiaki; Tochihara, Shinji; Kimachi, Kazuhiko; Kino, Yoichiro; Ueda, Kohji; Naruse, Takeshi; Fukuda, Tadashi

doi:10.1016/j.vaccine.2015.09.022

Record: found
Abstract: found
Article: not found

A clinical phase I study of an EB66 cell-derived H5N1 pandemic vaccine adjuvanted with AS03.

Author(s): Takeshi Naruse ¹ , Tadashi Fukuda ² , Tetsuro Tanabe ¹ , Munetaka Ichikawa ¹ , Yoshiaki Oda ¹ , Shinji Tochihara ¹ , Kazuhiko Kimachi ¹ , Yoichiro Kino ¹ , Kohji Ueda ³

Publication date (Electronic): Nov 09 2015

Journal: Vaccine

Publisher: Elsevier BV

Keywords: AS03, Cell culture-derived pandemic vaccine, EB66 cell, H5N1 influenza, JapicCTI-080586

Read this article at

ScienceOpenPublisher PubMed

Bookmark

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

We conducted a phase I clinical trial of a cell culture-derived AS03-adjuvanted influenza vaccine containing HA antigen (A/Indonesia/05/2005(H5N1)/PR8-IBCDC-RG2) derived from EB66 cells (KD-295).

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Vaccine

Title: Vaccine

Publisher: Elsevier BV

ISSN (Electronic): 1873-2518

ISSN (Print): 0264-410X

Publication date (Electronic): Nov 09 2015

Volume: 33

Issue: 45

Affiliations

[1 ] The Chemo-Sero-Therapeutic Research Institute (KAKETSUKEN), Kumamoto, Japan.

[2 ] The Chemo-Sero-Therapeutic Research Institute (KAKETSUKEN), Kumamoto, Japan. Electronic address: fukuda@kaketsuken.or.jp.

[3 ] Seinan Jo Gakuin University, Fukuoka, Japan.

Article

Publisher Item ID: S0264-410X(15)01286-4

DOI: 10.1016/j.vaccine.2015.09.022

PubMed ID: 26409141

SO-VID: 3a2c6a85-060b-49ab-b36b-fde68078e5a4

History

Keywords: JapicCTI-080586,AS03,Cell culture-derived pandemic vaccine,EB66 cell,H5N1 influenza

Data availability:

Keywords: JapicCTI-080586, AS03, Cell culture-derived pandemic vaccine, EB66 cell, H5N1 influenza

A clinical phase I study of an EB66 cell-derived H5N1 pandemic vaccine adjuvanted with AS03.

Read this article at

Abstract

Related collections

Malaria vaccine development

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Similar content 206

Cited by 3